Integrating novel agents into multiple myeloma treatment - current status in Switzerland and treatment recommendations.

Détails

Ressource 1Télécharger: BIB_8873EB254E5F.P001.pdf (282.37 [Ko])
Etat: Public
Version: de l'auteur⸱e
ID Serval
serval:BIB_8873EB254E5F
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Integrating novel agents into multiple myeloma treatment - current status in Switzerland and treatment recommendations.
Périodique
Swiss Medical Weekly
Auteur⸱e⸱s
Taverna C., Bargetzi M., Betticher D., Gmür J., Gregor M., Heim D., Hess U., Ketterer N., Lerch E., Matthes T., Mey U., Pabst T., Renner C.
ISSN
1424-3997 (Electronic)
ISSN-L
0036-7672
Statut éditorial
Publié
Date de publication
2010
Volume
140
Pages
w13054
Langue
anglais
Notes
Publication types: Comparative Study ; Consensus Development Conference ; Journal Article ; Research Support, Non-U.S. Gov't ; Review Publication Status: epublish
Résumé
The treatment of multiple myeloma has undergone significant changes in the recent past. The arrival of novel agents, especially thalidomide, bortezomib and lenalidomide, has expanded treatment options and patient outcomes are improving significantly. This article summarises the discussions of an expert meeting which was held to debate current treatment practices for multiple myeloma in Switzerland concerning the role of the novel agents and to provide recommendations for their use in different treatment stages based on currently available clinical data. Novel agent combinations for the treatment of newly diagnosed, as well as relapsed multiple myeloma are examined. In addition, the role of novel agents in patients with cytogenetic abnormalities and renal impairment, as well as the management of the most frequent side effects of the novel agents are discussed. The aim of this article is to assist in treatment decisions in daily clinical practice to achieve the best possible outcome for patients with multiple myeloma.
Mots-clé
Aged, Antineoplastic Agents/adverse effects, Antineoplastic Agents/therapeutic use, Biopsy, Needle, Bone Marrow/drug effects, Bone Marrow/pathology, Bone Marrow Transplantation, Boronic Acids/adverse effects, Boronic Acids/therapeutic use, Combined Modality Therapy, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Resistance, Neoplasm, Evidence-Based Medicine, Humans, Middle Aged, Multiple Myeloma/diagnosis, Multiple Myeloma/drug therapy, Neoplasm Recurrence, Local/drug therapy, Neoplasm Recurrence, Local/pathology, Plasma Cells/drug effects, Plasma Cells/pathology, Pyrazines/adverse effects, Pyrazines/therapeutic use, Retreatment, Type="Geographic">Switzerland, Thalidomide/adverse effects, Thalidomide/analogs & derivatives
Pubmed
Web of science
Création de la notice
25/08/2010 12:46
Dernière modification de la notice
20/08/2019 14:47
Données d'usage